Mydecine Innovations Group Inc
Change company Symbol lookup
Select an option...
MYCOF Mydecine Innovations Group Inc
ALGN Align Technology Inc
PPG PPG Industries Inc
VFFVX Vanguard Target Retirement 2055 Fund Investor Shares
LUB Luby's Inc
AZO Autozone Inc
RMAX Re/Max Holdings Inc
SWET Athlon Acquisition Corp
ETR Entergy Corp
KUBTY Kubota Corp
Go

Health Care : Pharmaceuticals | Small Cap Value
Based in Canada
Company profile

Mydecine Innovations Group Inc. is a Canada-based biopharma and life sciences company. The Company is focused on the research, development and acceptance of alternative nature-sourced medicine. Its portfolio of companies includes Mydecine Health Sciences (MHS), Mindleap Health Inc. (Mindleap) and NeuroPharm, Inc (NPI). MHS is focused on developing fungtional mushroom products and psychedelic medicines for the consumer and professional healthcare market. NPI is a veterans-focused healthcare company that is developing pharmaceutical and natural health products for mental wellness in vulnerable populations, including veterans, emergency medical services (EMS) personnel and other high-risk constituencies. NPI is developing psilocybin-assisted psychotherapy to treat chronic post-traumatic stress disorder (PTSD). Mindleap offers a digital health platform that enables people connect with mental health specialists, who can help them to develop habits for a healthy mind.

Closing Price
$0.2718
Day's Change
-0.0031 (-1.13%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.28
Day's Low
0.25
Volume
(Light)
Volume:
398,195

10-day average volume:
678,724
398,195

Display:

Providers:

UpdateCancel
6 providers
March 23, 2021
Mydecine Innovations Group Announces Migration to NEO Exchange

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...(Globe Newswire)

March 16, 2021
Mydecine Innovations Group Provides Update on European Operations

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine...(Globe Newswire)

March 10, 2021
Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.] Cannabis Assets

*NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), is pleased to announce that it has entered into an...(Globe Newswire)

March 01, 2021
Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma company in the life sciences category committed to the research and development, production, and acceptance of alternative...(Globe Newswire)

February 24, 2021
Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Partnership Supports Mydecine's Drug Development & Clinical Trials Pipeline Provides Update on Debt Settlement *NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES (Globe Newswire)

February 17, 2021
Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap's Mental Health Technology

Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company") is pleased to announce that its subsidiary Mindleap Health ("Mindleap"), a digital health platform and the world's-first telemedicine application...(Globe Newswire)

February 03, 2021
Mydecine Innovations Group Appoints Josephine Wu to Board of Directors

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...(Globe Newswire)

February 01, 2021
Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...(Globe Newswire)

January 28, 2021
Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine...(Globe Newswire)

January 27, 2021
Mydecine Innovations Group Files Application to list to the NASDAQ

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...(Globe Newswire)

January 22, 2021
Mydecine Innovations Group Included in First-Ever Psychedelics ETF

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.